Selank

In simple terms, Selank helps the brain: reduce anxiety, improve focus, stay calm without sedation.

SKU: BND3-SEL Category:

Product Details

Parameter Specification
Purity ≥ 99% (HPLC, third-party tested)
Form Lyophilized peptide powder
Content 10 mg Selank per vial
Appearance White to off-white powder
Packaging Glass vial with sterile closure
Storage Conditions 2–8 °C (lyophilized), protect from light, keep desiccated
Molecular Formula C33H57N11O9
Molecular Weight ≈ 751.9 g·mol¹
Amino Acid Sequence Thr–Lys–Pro–Arg–Pro–Gly–Pro (7 aa)
CAS Number 129954-34-3
Solubility Bacteriostatic water

Overview

Selank is a synthetic neuropeptide derived from the endogenous immune peptide tuftsin. It is a modified heptapeptide with the sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is classified as: a neuropeptide regulator, an anxiolytic and cognitive modulator, a link between the immune and nervous systems (Kozlovskii et al., 2003).

What it is and how it works

Selank acts in the CNS as a neuromodulator, influencing: GABAergic system, serotonergic system, dopaminergic pathways. It modulates: GABA receptor activity, serotonin metabolism, neurotrophic signaling. Unlike benzodiazepines: minimal sedation, low dependence potential (Kost et al., 2015).

Effects confirmed by research

1. Anxiolytic effects

  • reduced anxiety, emotional stabilization (Kozlovskii et al., 2003).

2. Cognitive enhancement

  • improved memory, better learning (Zozulya et al., 2008).

3. Stress modulation

  • reduced stress response, serotonin regulation (Kost et al., 2015).

4. Neuroimmune effects

  • cytokine modulation, immune system interaction (Ashmarin et al., 2005).

5. Neuroprotection

  • neuronal protection, improved neuroplasticity.

Scientific description

Selank is: a tuftsin-derived peptide, regulator of: GABA signaling, serotonin pathways, neuroimmune interactions.

References

Kozlovskii, I. I., et al. Selank anxiolytic effects. 2003. Kost, N. V., et al. Neurotransmitter modulation. 2015. Zozulya, A. A., et al. Cognitive effects. 2008. Ashmarin, I. P., et al. Neuropeptides and immunity. 2005.